Clinical Trials Directory

Trials / Completed

CompletedNCT01088399

A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults

The Global Hypopituitary Control and Complications Study

Status
Completed
Phase
Study type
Observational
Enrollment
10,673 (actual)
Sponsor
Eli Lilly and Company · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The Hypopituitary Control and Complications Study "HypoCCS" is a prospective, open label, global, multicentre, observational study on routine clinical care of adults with growth hormone deficiency occurring either isolated or in combination with other pituitary hormone deficiencies. The objective of this observational study is to evaluate long-term safety and health outcomes for adult growth hormone deficient participants with or without somatropin replacement therapy. As an observational study, data are collected only as provided at the discretion of the attending physician. The participant enrolled meet the criteria of growth hormone deficiency in adults as per the Humatrope label in the country where their attending physician practices, and this diagnosis is at the discretion of the attending physician. The decision to receive somatropin or remain untreated is made by the participant in consultation with their attending physician. While treatment of adult growth hormone deficient participants with somatropin has been shown to be safe and effective in clinical trials of 18 months duration, this observational study aims to provide information on health outcome and replacement therapy over longer periods of time for a larger number of participants in the context of the overall disease environment.

Conditions

Interventions

TypeNameDescription
DRUGSomatropin (rDNA origin)Dose, frequency and duration are at discretion of attending physician, and determined on an individual basis.

Timeline

Start date
2002-09-01
Primary completion
2012-12-01
Completion
2012-12-01
First posted
2010-03-17
Last updated
2014-04-21
Results posted
2014-04-21

Source: ClinicalTrials.gov record NCT01088399. Inclusion in this directory is not an endorsement.